Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04172844 · ClinicalTrials.gov registry record · Phase 1
Pevonedistat, Azacitidine (or Decitabine), and Venetoclax for the Treatment of Patients With Acute Myelogenous Leukemia
A Phase 1 study, sponsored by Medical College of Wisconsin.
- Terminated
- Registry status
- Phase 1
- Development phase
- 16
- Enrollment target
NCT04172844 is a Phase 1 study that was terminated before completion, run by Medical College of Wisconsin. The registered enrollment target is 16 participants.
The verdict
NCT04172844, a Phase 1 study, was terminated before completion, sponsored by Medical College of Wisconsin.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 16 participants
- Enrollment target
Study Summary
This is a phase Ib study with a 3 + 3 dose escalation design followed by a dose-expansion phase.
Interventions
- DRUG Venetoclax
- DRUG Azacitidine
- DRUG Pevonedistat
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2020-01-13 |
| Est. Completion | 2022-02-27 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04172844
The ClinicalTrials.gov registry entry for NCT04172844 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Medical College of Wisconsin, which has 447 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Venetoclax is the first listed.
NCT04172844 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04172844 about?
NCT04172844 is a clinical study titled "Pevonedistat, Azacitidine (or Decitabine), and Venetoclax for the Treatment of Patients With Acute Myelogenous Leukemia". This is a phase Ib study with a 3 + 3 dose escalation design followed by a dose-expansion phase.
What is the current status of trial NCT04172844?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2020-01-13. Estimated completion is 2022-02-27.
What interventions are being tested in trial NCT04172844?
The interventions under investigation include: Venetoclax (DRUG), Azacitidine (DRUG), Pevonedistat (DRUG).
Who is sponsoring clinical trial NCT04172844?
This trial is sponsored by Medical College of Wisconsin, which has 447 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.